Neuronal surface antigen antibodies in limbic encephalitis
Open Access
- 16 September 2008
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 71 (12), 930-936
- https://doi.org/10.1212/01.wnl.0000325917.48466.55
Abstract
Objective: To report the frequency and type of antibodies against neuronal surface antigens (NSA-ab) in limbic encephalitis (LE). Methods: Analysis of clinical features, neuropathologic findings, and detection of NSA-ab using immunochemistry on rat tissue and neuronal cultures in a series of 45 patients with paraneoplastic (23) or idiopathic (22) LE. Results: NSA-ab were identified in 29 patients (64%; 12 paraneoplastic, 17 idiopathic). Thirteen patients had voltage-gated potassium channels (VGKC)-ab, 11 novel NSA (nNSA)-ab, and 5 NMDA receptor (NMDAR)-ab. nNSA-ab did not identify a common antigen and were more frequent in paraneoplastic than idiopathic LE (39% vs 9%; p = 0.03). When compared with VGKC-ab or NMDAR-ab, the nNSA associated more frequently with intraneuronal antibodies (11% vs 73%; p = 0.001). Of 12 patients (9 nNSA-ab, 2 VGKC-ab, 1 NMDAR-ab) with paraneoplastic LE and NSA-ab, concomitant intraneuronal antibodies occurred in 9 (75%). None of these 12 patients improved with immunotherapy. The autopsy of three of them showed neuronal loss, microgliosis, and cytotoxic T cell infiltrates in the hippocampus and amygdala. These findings were compatible with a T-cell mediated neuronal damage. In contrast, 13 of 17 (76%) patients with idiopathic LE and NSA-ab (8 VGKC-ab, 4 NMDAR-ab, 1 nNSA-ab) and 1 of 5 (20%) without antibodies had clinical improvement (p = 0.04). Conclusions: In paraneoplastic limbic encephalitis (LE), novel antibodies against neuronal surface antigens (nNSA-ab) occur frequently, coexist with antibodies against intracellular antigens, and these cases are refractory to immunotherapy. In idiopathic LE, the likelihood of improvement is significantly higher in patients with NSA-ab than in those without antibodies. GLOSSARY: GAD = glutamic acid decarboxylase; LE = limbic encephalitis; NMDAR = N-methyl-D-aspartate receptor; NSA = neuronal surface antigens; nNSA = novel NSA; SCLC = small-cell lung cancer; VGKC = voltage-gated potassium channels; WBC = white blood cells.This publication has 23 references indexed in Scilit:
- Paraneoplastic limbic encephalitis associated with potassium channel antibodies: value of anti-glial nuclear antibodies in identifying the tumourJournal of Neurology, Neurosurgery & Psychiatry, 2007
- Paraneoplastic anti–N‐methyl‐D‐aspartate receptor encephalitis associated with ovarian teratomaAnnals of Neurology, 2007
- Voltage-gated potassium channel antibodies associated limbic encephalitis in a patient with invasive thymomaJournal of the Neurological Sciences, 2006
- Rapid eye movement sleep behavior disorder and potassium channel antibody–associated limbic encephalitisAnnals of Neurology, 2005
- Anti-glial nuclear antibody: Marker of lung cancer-related paraneoplastic neurological syndromesJournal of Neuroimmunology, 2005
- Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlatesBrain, 2005
- Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysinThe Lancet, 2005
- T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitisNeurology, 1998
- 1G5: a calmodulin-binding, vesicle-associated, protein kinase-like protein enriched in forebrain neuritesJournal of Neuroscience, 1994
- Response of the Lambert‐Eaton myasthenic syndrome to treatment of associated small‐cell lung carcinomaNeurology, 1990